title: Lewis and Sumner syndrome following infliximab treatment in Crohn's disease: a report of 2 cases.
authors.forename: Stephane
authors.initials: S
authors.lastname: Nancey
authors.forename: Françoise
authors.initials: F
authors.lastname: Bouhour
authors.forename: Gilles
authors.initials: G
authors.lastname: Boschetti
authors.forename: Christophe
authors.initials: C
authors.lastname: Magnier
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Gonneau
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Souquet
authors.forename: Dominique
authors.initials: D
authors.lastname: Kaiserlian
authors.forename: Bernard
authors.initials: B
authors.lastname: Flourie
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000069285:Infliximab; D016472:Motor Neuron Disease / Q000139:chemically induced* / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab